Article
CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy
26 Aug 2021
Abstract excerpt
Cancer immunotherapy has gained attention as the supreme therapeutic modality for the treatment of various malignancies. Adoptive T-cell therapy (ACT) is one of the most distinctive modalities of this therapeutic approach, which seeks to harness the potential of combating cancer cells by using autologous or allogenic tumor-specific T-cells. However, a plethora of circumstances must be optimized to produce...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
